Methods and systems for preparing blood products

Abstract

Methods and systems for preparing blood products that are ready for treatment in established pathogen inactivation procedures are disclosed. The methods include providing a source of a blood component and combining the blood component with a synthetic medium in a selected ratio of the blood component to the synthetic media, whereby the resulting blood product is treatment-ready.

1 - 10 . (canceled)  
   
   
       11 . A method for preparing a blood platelet product including platelets, a synthetic storage medium and plasma, said method comprising: 
 providing a container system comprising an interim container and a container including a liquid synthetic platelet storage medium, wherein said medium container is in flow communication with said interim container;    providing a source container including a quantity of platelets suspended in plasma;    attaching said source container to said interim container;    transferring said platelets suspended in plasma to said interim container;    combining said platelets suspended in plasma with said synthetic storage medium to achieve a selected ratio of synthetic storage medium and plasma.    
   
   
       12 . The method of  claim 11  comprising: 
 providing a container system further comprising an excess fluid container;    separating said platelets into concentrated platelets and plasma after transferring said platelets to said interim container, but before combining said platelets with said storage medium;    transferring a selected amount of said separated plasma to said excess fluid container;    introducing a selected amount of said storage medium into said interim container; and    transferring, if necessary, plasma from said excess fluid container to said interim container to achieve said relative quantities.    
   
   
       13 . The method of  claim 12  comprising transferring approximately 250-350 ml of 3×10 11  platelets to said interim container; and 
 transferring approximately 180-200 ml of plasma to said excess fluid container.    
   
   
       14 . The method of  claim 13  comprising adding approximately 180 ml of synthetic storage medium to said concentrated platelets.  
   
   
       15 . The method of  claim 11  comprising providing a container including a synthetic storage medium comprising approximately sodium chloride, sodium citrate, sodium acetate and sodium phosphate.  
   
   
       16 . The method of  claim 15  comprising providing a container including a synthetic storage medium comprising approximately 45-120 mM sodium chloride, approximately 5-15 mM sodium citrate, approximately 20-40 mM sodium acetate and approximately 20-40 sodium phosphate.  
   
   
       17 . The method of  claim 15  comprising providing a container including a synthetic storage medium comprising approximately 77.4 mM sodium chloride, approximately 10.8 mM sodium citrate, approximately 32.5 mM sodium acetate and approximately 28.2 mM sodium phosphate.  
   
   
       18 . The method of  claim 11  further comprising attaching said interim container to a disposable pathogen inactivation processing set after said combining step.  
   
   
       19 . The method of  claim 11  wherein said relative quantities of synthetic storage medium and platelets suspended in plasma is approximately 60-70% storage medium to 30-40% platelets in plasma.  
   
   
       20 . A container system for preparing a blood platelet product including platelets, a synthetic storage medium and plasma, the container system comprising: 
 an empty interim container and a flow path for providing flow communication with a container including a synthetic storage medium comprising sodium chloride, sodium citrate, sodium acetate and sodium phosphate;    a flow control device associated with said flow path;    said interim container being adapted for sterile connection to a platelet source comprising at least one therapeutic dose of platelets.    
   
   
       21 . The container system of  claim 20  further comprising an empty excess fluid container and a flow path providing for flow communication between said excess fluid and interim container.  
   
   
       22 . The container system of  claim 20  wherein said synthetic storage medium comprises approximately 45-120 mM sodium chloride, approximately 5-15 mM sodium citrate, approximately 20-40 mM sodium acetate and approximately 20-40 sodium phosphate.  
   
   
       23 . The container system of  claim 20  wherein said synthetic storage medium comprises approximately 77.4 mM sodium chloride, approximately 10.8 mM sodium citrate, approximately 32.5 mM sodium acetate and approximately 28.2 mM sodium phosphate.  
   
   
       24 . The container system of  claim 20  wherein said interim container comprises a flow path for establishing flow communication with a disposable pathogen inactivation processing set.